Save up -80% on Solifenacin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Vesicare
|$368.98||30 tablets/10 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Vesicare coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Solifenacin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Solifenacin volume of distribution
Solifenacin has an apparent volume of distribution of 600 L, is 93-96% plasma protein bound, and probably crosses the blood-brain barrier. Solifenacin is eliminated mainly through hepatic metabolism via cytochrome P450 (CYP) 3A4, with about only 7% (3-13%) of the dose being excreted unchanged in the urine.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Solifenacin
Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence.[Wikipedia]
Solifenacin mechanism of action
Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of incontinence episodes.
Dosage forms of Solifenacin
Actavis Pharma Company
Humans and other mammals
Indication of Solifenacin
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Toxicity of Solifenacin
Overdosage with solifenacin can potentially result in severe anticholinergic effects and should be treated accordingly. The highest solifenacin dose given to human volunteers was a single 100 mg dose. Intolerable anticholinergic side effects (fixed and dilated pupils, blurred vision, failure of heel-to-toe exam, tremors and dry skin) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose).
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Solifenacin on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Solifenacin now!
What is a Vesicare?
Vesicare – antispasmodic, it is a specific competitive inhibitor of muscarinic cholinergic receptors, mainly M3-subtype. It has also been found that solifenacin has a low affinity or lack of affinity for various other receptors and ion channels.
The efficacy of Vesicare when used in doses of 5 mg and 10 mg in overactive bladder syndrome is observed during the first week of treatment and stabilizes over the next 12 weeks of treatment. The maximum Vesicare effect can be detected after 4 weeks. Efficiency persists for prolonged use (at least 12 months).
After ingestion of Cmax in blood plasma is reached after 3-8 hours. Absolute bioavailability is 90%. Eating does not affect the Cmax and AUC of solifenacin. The pharmacokinetics of drug are linear in the therapeutic dose range. Vesicare is extensively metabolized in the liver, predominantly by the CYP3A4 isoenzyme. However, there are alternative metabolic pathways for solifenacin. The systemic clearance of Vesicare is about 9.5 l/h, and the final T1/2 is 45-68 h. After taking the drug inside the plasma, in addition to solifenacin, the following metabolites were identified: one pharmacologically active and three inactive. After a single injection, about 70% of the radioactivity was detected in the urine and 23% in the feces. In the urine, about 11% of the radioactivity was detected as unchanged active substance, about 18% as N-oxide metabolite, 9% as 4R-hydroxy-N-solifenacin oxide and 8% as 4R-hydroxy metabolite.